Prevalence and associated factors of metabolic dysfunction-associated steatotic liver disease in Taiwan, 2001-2021 [0.03%]
台湾2001-2021年与代谢紊乱相关脂肪肝病的流行及影响因素分析
Ming-Lun Yeh,Pei-Chien Tsai,Chung-Feng Huang et al.
Ming-Lun Yeh et al.
Background and aim: Metabolic dysfunction-associated steatotic liver disease (MASLD) was the most rapidly growing liver disease worldwide. We aimed to investigate the temporal trends in prevalence and risks of MASLD in Ta...
Efficacy of tirzepatide versus SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease (MASLD): a multicenter propensity-matched real-world study [0.03%]
司美格鲁肽与SGLT2抑制剂治疗代谢性肝病的疗效：一项基于真实世界数据的倾向匹配研究
Ibrahim Khalil,Pallab Sarker,Nabila Nur et al.
Ibrahim Khalil et al.
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent condition with significant cardiometabolic and hepatic risks. Tirzepatide, a dual GLP-1/GIP receptor agonist, shows promise in MA...
APASL clinical practice guidance: the diagnosis and management of patients with Wilson's disease [0.03%]
亚太肝脏研究学会临床实践指导：威尔森病的诊断与治疗
Wei Zhang,Hong You,Xiaojuan Ou et al.
Wei Zhang et al.
Pathological transcriptional retention of Cyp26b1 in perirenal adipose-derived stem cells contributes to MASLD progression [0.03%]
肾周脂肪来源干细胞中Cyp26b1转录滞留的病理学变化促进MASLD进展
Yannan Zhang,Zheng Li,Jinyu Sun et al.
Yannan Zhang et al.
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent liver disorder linked to metabolic syndrome, but its extrahepatic drivers and persistence mechanisms remain unclear. ...
APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update [0.03%]
亚太肝脏研究学会慢性乙型肝炎管理临床实践指南：2026年更新版
Hong You,Rakhi Maiwall,Jing Chen et al.
Hong You et al.
Globally, especially in the Asia Pacific region, chronic hepatitis B infection has led to an undesirable escalating morbidity and mortality with acute-on chronic liver failure, end-staged liver cirrhosis, and hepatocellular carcinoma. This ...
Efficacy of radiation therapy plus targeted therapy with or without immunotherapy for lymph node metastases in hepatocellular carcinoma [0.03%]
放疗联合靶向治疗及/或免疫治疗肝细胞癌淋巴结转移的有效性研究
Li Zhang,Maopei Chen,Jing Sun et al.
Li Zhang et al.
Background and aims: This study aimed to investigate the efficacy of radiation therapy and targeted therapy combined with or without immunotherapy for hepatocellular carcinoma (HCC) patients with lymph node metastases (LN...
Trends in MASLD-related cirrhosis and liver cancer across diverse populations, 2010-2023 [0.03%]
2010-2023年美国不同人群MASLD相关肝硬化和肝癌的流行趋势
Jialin Wu,Bonan Chen,Fuda Xie et al.
Jialin Wu et al.
Background/aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is now a leading cause of liver complications. This study aims to evaluate the temporal trends in the burden of MASLD-related cirrhosis and...
Spatial analysis identifies LAMTOR2 overexpression in hepatocellular carcinoma with vessels encapsulating tumor clusters [0.03%]
空间分析发现肝细胞癌中LAMTOR2过度表达（肿瘤簇被血管包裹）
Yoon Jung Hwang,San Ha Hwang,Min Ji Kang et al.
Yoon Jung Hwang et al.
Background: Vessels encapsulating tumor clusters (VETC) is a distinct angiogenic pattern in hepatocellular carcinoma (HCC). While VETC-positive HCC is associated with poor prognosis, it demonstrates improved responses to ...
Alcohol consumption and dementia risk in steatotic liver disease: a nationwide cohort study [0.03%]
酒精消耗和脂肪肝疾病患者的痴呆风险：一项全国队列研究
Ji Won Han,Seunghee Na,Kyungdo Han et al.
Ji Won Han et al.
Background: The relationship between steatotic liver disease (SLD) and dementia remains unclear, particularly regarding alcohol consumption patterns. We investigated the risk of dementia across SLD subtypes classified by ...
Beyond "left or right": future implications for study design and endpoints in TIPS portal branch selection [0.03%]
超越"左与右"：未来经颈静脉肝内门体分流术侧支选择的研究设计及结局指标的启示
Xuyang Liu,Ze Bo,Yanchen Zhong et al.
Xuyang Liu et al.